Karolinska Development’s portfolio company AnaCardio’s founder publishes article that supports development of heart failure drug candidate AC01
STOCKHOLM, SWEDEN March 14, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the founder of its portfolio company AnaCardio, Professor Lars Lund, has published an article on a heart failure study in the scientific journal European Heart Journal. The study's publication reinforces the company’s efforts to develop a novel treatment for heart failure based on proof-of-concept established by the study.
The scientific journal European Heart Journal publication is based on a study led by Professor Lars Lund, performed in cooperation with researchers at Karolinska Institutet and Karolinska University Hospital. The study, which evaluated the peptide hormone ghrelin as a novel treatment in patients with heart failure and in isolated heart cells in the laboratory, showed an increase in contractility and demonstrated a novel molecular mode of action.
The study was randomized, double-blind, and placebo-controlled and included 30 patients with heart failure. The patients were randomly assigned to either active treatment with ghrelin or placebo given intravenously for two hours. Treatment with ghrelin increased the volume of blood pumped by the heart by 28 percent, compared to no effect in the placebo group. No serious adverse reactions were observed and no signs of arrhythmia, ischemia, or hypotension were detected. The underlying mechanisms behind the increased pump function were evaluated and identified in preclinical models in isolated heart cells in the laboratory.
Based on this well-documented mode of action, Anacardio has initiated a clinical study to evaluate the drug candidate AC01, a small molecule mimicking the mode of action of ghrelin with great potential to safely enhance the contractions of the heart in heart failure patients.
”The development program for AC01, which has the same mode of action as ghrelin, is based on these study results. The publication of the article in the reputable journal European Heart Journal verifies the scientific hypothesis behind AnaCardio’s unique pharmaceutical project and sheds light on a novel treatment with great potential to help patients with heart failure,” says Viktor Drvota, CEO, Karolinska Development.
Karolinska Development’s ownership interest in AnaCardio amounts to 21 percent.
Publication: Lund LH, Hage C, Pironti G, Thorvaldsen T, Ljung-Faxén U, Zabarovskaja S, Shahgaldi K, Webb D, Hellström PM, Andersson DC, Ståhlberg M.
Acyl ghrelin improves cardiac function in heart failure and increases fractional shortening in cardiomyocytes without calcium mobilization. Eur Heart J 2023; doi: 10.1093/eurheartj/ehad100, https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehad100
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: firstname.lastname@example.org
Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: email@example.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
ObsEva Files Year End 2022 Financial Statements31.3.2023 22:01:00 CEST | Press release
ObsEva FilesYear End 2022 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 31, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market: OBSVF), a biopharmaceutical company developing and commercializing novel therapies to improve women’s health, today published its U.S. Annual Report on Form 10-K for Fiscal Year 2022, including the U.S. GAAP financial results for year-end 2022. The U.S. Annual Report on Form 10-K can be accessed in the financial section of the Company’s website, here or directly via the link here. ObsEva expects to publish its Swiss Annual Report to Shareholders, including the financial results for year end 2022 in IFRS, in the week commencing April 24, 2023. About ObsEva ObsEva is a biopharmaceutical company developing novel therapies to improve women’s reproductive health and pregnancy. ObsEva has established a development program focused on improving in vitro fertilization success rates. ObsEva is listed on
Oxurion Publishes 2022 Annual Report31.3.2023 20:42:16 CEST | Press release
Regulated Information Leuven, BELGIUM,Boston, MA, US–March 31, 2023– 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, published its annual report for the financial year 2022. The annual report for the year ending December 31, 2022 is available in the “Investors” section of the Company’s website, and can also be downloaded as a PDF. About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeut
Iceland Seafood International hf completes auction of bills31.3.2023 20:33:29 CEST | Press release
Iceland Seafood International hf. has concluded an offering of 3-month bills in the new series ICESEA 23 0705. Total offers for bills in the auction amounted to ISK 1.500 million which were all accepted, at a simple rate of 11.00%. The bills are scheduled to be admitted to trading on Nasdaq Iceland in the coming weeks.
Nokia Corporation: Repurchase of own shares on 31.03.202331.3.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 31 March 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 31.03.2023 Espoo, Finland – On 31 March 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL221,1864.49CEUX21,0654.50AQEU12,3894.49TQEX7,3604.50Total262,0004.49 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 a
Fly Play hf.: Amendments to share option plan31.3.2023 20:00:00 CEST | Press release
Amendments to share option plan As detailed in the Company Description in relation to the listing of shares in Fly Play hf. on Nasdaq First North Iceland, dated June 2021, the Company had, in accordance with the remuneration then in force, implemented a share-based incentive program in the form of option rights whereby the Company granted several members of the management team and other key employees options to purchase shares in the Company as part of their remuneration. Having regard for the purposes of the share-based incentive program referred to above, the Board of Directors has decided to extend the exercise period in relation to share options to purchase a total of 16.666.669 shares in the Company, at a purchase price of ISK 8 per share. For a period of 12 months, these options are therefore exercisable until April 2024, at which point the options expire. The options may be exercised at any time during the exercise period.